Christina Scully
About Christina Scully
Christina Scully is the Director of Biologics Manufacturing at Bristol-Myers Squibb, with over 15 years of experience in the biotech industry and a strong background in biochemistry.
Company
Christina Scully is currently employed at Bristol-Myers Squibb as the Director of Biologics Manufacturing. Her role likely involves overseeing the production processes for biologic drugs and ensuring compliance with industry standards. Prior to this, she held a significant position at Wyeth Biotech, serving as the Director of Process Tech Services. This blend of roles highlights her expertise and leadership in both biologics and process technology.
Title
Christina Scully holds the title of Director, Biologics Manufacturing. Her responsibilities likely include managing the end-to-end production process for biologics, overseeing quality control, and ensuring regulatory compliance. Her leadership extends to coordinating with various teams within the organization to streamline manufacturing operations.
Education and Expertise
Christina Scully earned her Master of Science degree in Biochemistry from the University of Michigan. This strong educational background in biochemistry supports her extensive experience in the biotech industry. With over 15 years in biologics manufacturing, she has developed a deep understanding of the scientific and operational aspects of the field.
Background
Christina Scully began her career in the biotech industry in 1990 at Serono, where she worked as a Senior Technical Operations Scientist for seven years until 1997. This foundation in technical operations has been a cornerstone of her professional development, contributing significantly to her later roles in biologics manufacturing and process technology services.
Experience in Biologics Manufacturing
With over 15 years of experience in biologics manufacturing, Christina Scully has a proven track record in managing complex production processes. Her roles have consistently involved ensuring product quality and compliance with stringent industry standards. Her leadership at both Bristol-Myers Squibb and Wyeth Biotech underscores her significant contributions to the field.